Shepherd Therapeutics aims to Develop Therapies for Rare Cancers

‘Cancer’, just the mere mention of this word triggers awful thoughts in one’s mind circling around medical suffering and a painful death. Cancer is the second leading cause of death worldwide which justifies the fear that comes with it. Even though researchers are trying their level best to find medical solutions for the same, this disease causes more than 8 million deaths every year. Out of this, more than 42 percent of deaths take place due to rare cancer. There are around 250 types of rare cancers, but only 38 of them have approved target therapies. This has made rare cancer the third leading cause of death in the U.S. A biotech startup Shepherd Therapeutics works to find target therapies for the rest of the rare cancer diseases.

David Hysong is a 29-year-old entrepreneur who has recently attained a place in the Forbes 30 under 30 list in the field of science. When he was diagnosed with a rare head-and-neck cancer in the year of 2015, he came up with the idea of Shepherd Therapeutics. This biotech startup works to identify rare cancers which do not have healing therapies to work accordingly. It is important to note that another reason behind the rising number of deaths due to cancer is that a majority of the patients can’t afford such expensive treatments. This startup not only focuses on medical development but also its cost efficiency. The researchers are working to develop such therapeutics in a faster yet cost efficient manner compared to other cancer treatments.

Shepherd Therapeutics

Shepherd Therapeutics is working on developing treatments for rare cancers.

Foundation of the Shepherd Therapeutics

As soon as Hysong came up with the concept of Shepherd Therapeutics, he consulted Gene Williams. Williams is the executive chairman at ProMIS Neurosciences and has more than 30 years of experience in the field of biotech and an extensive network. Williams guided the company through hours of weekly mentoring. He helped Hysong with the interviews conducted and together they built a team of key members. Amalgamation of Williams’ experience along with Hysong’s vision might be the mantra behind the success of this startup. Williams helped build relations with the biotech ecosystem on a broader scale. This enabled the company to attain a fund worth $1.5 million in seed funding.

Currently, Shepherd Therapeutics is targeting Chordoma, Adenoid Cystic Carcinoma (ACC), Ewing’s Sarcoma, Adrenocortical Carcinoma, Neuroblastoma, and Rhabdomyosarcoma. This organization is mainly focusing on providing capital for such research. This is done by looking out for disease-specific research foundations which are working on ultra-low incidence cancers and fund them. Presently the organization is giving preference to rare cancers in women and children. Later on, the company strives to come up with target therapies for all types of cancer.

Carrie Ann
Carrie Ann is Editor-in-Chief at Industry Leaders Magazine, based in Las Vegas. Carrie covers technology, trends, marketing, brands, productivity, and leadership. When she isn’t writing she prefers reading. She loves reading books and articles on business, economics, corporate law, luxury products, artificial intelligence, and latest technology. She’s keen on political discussions and shares an undying passion for gadgets. Follow Carrie Ann on Twitter, Facebook

Recent Posts

General Motors Q2 2021 Results Recap

General Motors Q2 2021 Results Recap

General Motors Q2 earnings and revenue missed Wall Street’s expectations even though the world’s leading automaker beat earnings projections.
19 hours ago
UK casts doubt over Nvidia’s Arm acquisition over security risks

UK casts doubt over Nvidia’s Arm acquisition over security risks

UK considers blocking Nvidia’s Arm acquisition due to potential risks to national security. The $40 billion takeover faces similar fate in America, China and the European Union.
1 day ago
PepsiCo relinquishes control of Tropicana for $3.3 billion

PepsiCo relinquishes control of Tropicana for $3.3 billion

PepsiCo will sell Tropicana and other juice brands to a private equity firm in exchange for pre-tax proceeds of 3.3 billion dollars.
2 days ago
Sanofi bets big on mRNA future with Translate Bio acquisition offer

Sanofi bets big on mRNA future with Translate Bio acquisition offer

Sanofi’s CEO Paul Hudson is dead serious about mRNA technology and capabilities with a $3.2 billion acquisition offer to Translate Bio.
2 days ago
Top 6 Energy Dividend Stocks to include in your portfolio

Top 6 Energy Dividend Stocks to include in your portfolio

The entire energy sector yield hovers around 4%, according to the Energy Select Sector SPDR exchange-traded fund.
2 days ago
Monte dei Paschi performance below par in EU banks stress test

Monte dei Paschi performance below par in EU banks stress test

The depletion of capital at each bank under the test’s harshest scenario will be closely scrutinised, and could potentially lead to hostile takeovers
4 days ago